These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39115676)

  • 21. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study.
    Yuan J; Cheng F; Xiao G; Wang X; Fan H
    Front Oncol; 2022; 12():917089. PubMed ID: 35795060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
    Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
    BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
    Front Oncol; 2022; 12():894835. PubMed ID: 36203439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
    He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
    Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study.
    Wang J; Liang S; Xu L; Kong Y; Seki N; Ganti AK; Neal JW; Li J; Xu F; Li K; Xu Y; Wu L; Chen B
    J Thorac Dis; 2024 Jun; 16(6):3897-3908. PubMed ID: 38983156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
    Chen B; Wang J; Pu X; Li J; Wang Q; Liu L; Xu Y; Xu L; Kong Y; Li K; Xu F; Liang S; Cardona AF; Wu L
    Transl Lung Cancer Res; 2022 Oct; 11(10):2111-2124. PubMed ID: 36386462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis.
    Yao Y; Li B; Song R; Yang L; Zou B; Wang L
    Radiat Oncol; 2024 Feb; 19(1):25. PubMed ID: 38413988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
    Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer.
    Wang N; Zhao L; Zhang D; Kong F
    Anticancer Drugs; 2023 Apr; 34(4):558-562. PubMed ID: 36728981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib.
    Liu J; Li S; Zhang S; Yang C; Zhang L; Zhang B; Cheng Y; Wang C
    J Thorac Dis; 2020 Oct; 12(10):5765-5773. PubMed ID: 33209408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer.
    Zhang C; Wang J; Wang X; Meng Z; Cheng Y; Li K
    Cancer Biol Med; 2021 Jul; 19(8):1249-58. PubMed ID: 34302324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line immune-checkpoint inhibitor plus chemotherapy
    Landre T; Chouahnia K; Des Guetz G; Duchemann B; Assié JB; Chouaïd C
    Ther Adv Med Oncol; 2020; 12():1758835920977137. PubMed ID: 33343721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Xiong Q; Qin B; Xin L; Yang B; Song Q; Wang Y; Zhang S; Hu Y
    Front Oncol; 2021; 11():659380. PubMed ID: 34395243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
    Yin X; Liu X; Ren F; Meng X
    Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of immunotherapy as first-line treatment for extensive-stage small cell lung cancer: evaluating based on reconstructed individual patient data.
    Zhang S; Li S; Cheng Y
    Front Oncol; 2024; 14():1371313. PubMed ID: 39026980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.
    Wu Y; Zhou X; Zhao W; Wang Q; Han Z; Wang L; Zhou W; Zhou T; Song H; Chen Y; Yang K; Shi L; Pan B; Guo R; Zhou G; Jiang F; Feng J; Shen B
    Invest New Drugs; 2023 Dec; 41(6):825-833. PubMed ID: 37837490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
    Zhang W; Deng P; Kong T; Zhang B; Qian F; Dong Y; Chen Y; Chen L; Liu D; Zhang Y; Yang H; Han B
    Lung Cancer; 2022 Nov; 173():43-48. PubMed ID: 36116169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.